Gustavo P Amarante-Mendes

Prof. Dr. Gustavo P Amarante-Mendes

orcid

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
Gustavo P Amarante-MendesGustavo P Amarante-Mendes
Gustavo P Amarante-Mendes
SASandy Adjemian
Sandy Adjemian
LBLaura Migliari Branco
Laura Migliari Branco
LZLarissa C. Zanetti
Larissa C. Zanetti
RWRicardo Weinlich
Ricardo Weinlich
KARINA BORTOLUCIKARINA BORTOLUCI
KARINA BORTOLUCI
Pattern Recognition Receptors (PRRs) are proteins capable of recognizing molecules frequently found in pathogens (the so-called Pathogen-Associated Molecular Patterns—PAMPs), or molecules released by damaged cells (the Damage-Associated Molecular Patterns—DAMPs). They emerged phylogenetically prior to the appearance of the adaptive immunity and, therefore, are considered part of the innate immune system. Signals derived from the engagement of PRRs on the immune cells activate microbicidal and pro-inflammatory responses required to eliminate or, at least, to contain infectious agents. Molecularly controlled forms of cell death are also part of a very ancestral mechanism involved in key aspects of the physiology of multicellular organism, including the elimination of unwanted, damaged or infected cells. Interestingly, each form of cell death has its particular effect on inflammation and on the development of innate and adaptive immune responses. In this review article, we discuss some aspects of the molecular interplay between the cell death machinery and signals initiated by the activation of PRRs by PAMPs and DAMPs.

1 November 1996 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
SMSeamus J. Martin
Seamus J. Martin
DFDeborah M. Finucane
Deborah M. Finucane
Gustavo P Amarante-MendesGustavo P Amarante-Mendes
Gustavo P Amarante-Mendes
GOGeraldine A. O'Brien
Geraldine A. O'Brien
DGDouglas R. Green
Douglas R. Green
Phosphatidylserine (PS), a lipid normally confined to the inner leaflet of the plasma membrane, is exported to the outer plasma membrane leaflet during apoptosis to serve as a trigger for recognition of apoptotic cells by phagocytes. The mechanism of PS export during apoptosis is not known nor is it clear whether the nuclear changes that typify apoptosis contribute in any way to this event. Here, we demonstrate that ligation of the CD95 (Fas/APO-1) molecule on Jurkat cytoplasts induces dramatic PS externalization similar to that observed during apoptosis of intact cells. Apoptosis of both cells and cytoplasts was associated with proteolytic processing of CPP32, a member of the interleukin-1β converting enzyme (ICE)/CED-3 protease family, to its active form. Fodrin, a component of the cortical cytoskeleton, also underwent proteolytic cleavage during apoptosis of both cytoplasts and intact cells. Strikingly, CPP32 activation, fodrin proteolysis, and PS externalization were all inhibited in the presence of peptide inhibitors of ICE/CED-3 family proteases. These data provide strong support for the notion that the cell death machinery is extranuclear and is likely to be comprised of one or more members of the ICE/CED-3 family and that activation of this machinery does not require nuclear participation.

19 March 1998 in Oncogene
Verified
Journal Article
Closed access
Gustavo P Amarante-MendesGustavo P Amarante-Mendes
Gustavo P Amarante-Mendes
AMAnne J McGahon
Anne J McGahon
WNWalter K Nishioka
Walter K Nishioka
DADaniel Eh Afar
Daniel Eh Afar
OWOwen N Witte
Owen N Witte
DGDouglas R Green
Douglas R Green

7 April 1998 in Cell Death & Differentiation
Verified
Journal Article
Closed access
Gustavo P Amarante-MendesGustavo P Amarante-Mendes
Gustavo P Amarante-Mendes
DFDeborah M Finucane
Deborah M Finucane
SMSeamus J Martin
Seamus J Martin
TCTom Cotter
Tom Cotter
GSGuy S Salvesen
Guy S Salvesen
DGDouglas R Green
Douglas R Green

1 November 2001 in Current Biology
Verified
Journal Article
Closed access
JBJosé Mario de Freitas Balanco
José Mario de Freitas Balanco
MMMaria Elisabete Costa Moreira
Maria Elisabete Costa Moreira
ABAdriana Bonomo
Adriana Bonomo
PBPatricia Bozza
Patricia Bozza
Gustavo P Amarante-MendesGustavo P Amarante-Mendes
Gustavo P Amarante-Mendes
MBMarcello André Barcinski
Marcello André Barcinski

17 January 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Gustavo P Amarante-MendesGustavo P Amarante-Mendes
Gustavo P Amarante-Mendes
ARAamir Rana
Aamir Rana
TDTarcila Santos Datoguia
Tarcila Santos Datoguia
NHNelson Hamerschlak
Nelson Hamerschlak
GBGabriela Brumatti
Gabriela Brumatti
The constitutively active BCR-ABL1 tyrosine kinase, found in t(9;22)(q34;q11) chromosomal translocation-derived leukemia, initiates an extremely complex signaling transduction cascade that induces a strong state of resistance to chemotherapy. Targeted therapies based on tyrosine kinase inhibitors (TKIs), such as imatinib, dasatinib, nilotinib, bosutinib, and ponatinib, have revolutionized the treatment of BCR-ABL1-driven leukemia, particularly chronic myeloid leukemia (CML). However, TKIs do not cure CML patients, as some develop TKI resistance and the majority relapse upon withdrawal from treatment. Importantly, although BCR-ABL1 tyrosine kinase is necessary to initiate and establish the malignant phenotype of Ph-related leukemia, in the later advanced phase of the disease, BCR-ABL1-independent mechanisms are also in place. Here, we present an overview of the signaling pathways initiated by BCR-ABL1 and discuss the major challenges regarding immunologic/pharmacologic combined therapies.